Shingrix is a recombinant protein subunit-based vaccine and is generally used in favour of an older shingles vaccine – Merck & Co's Zostavax – which is cased on a live, attenuated virus.

In our opinion, the five most important issues facing RSV F protein subunit-based vaccines in the next 5–10 years are the following: Determining whether RSV F protein subunit vaccines will be ...

These fusion proteins are the basis of many subunit vaccines, a type in which a part of the pathogen being vaccinated against is injected to prompt the body to efficiently raise an immune response ...